Strong Revenue and EBITDA Growth
Total revenues for Q2 2025 were $654.8 million with an adjusted EBITDA of $48.1 million, representing a 35% year-over-year revenue growth, driven by the Care Partners segment and a shift to full risk arrangements.
Successful Prospect Health Acquisition
The acquisition of Prospect Health was closed at $708 million, down from the anticipated $745 million, reducing net debt to pro forma adjusted EBITDA leverage ratio to 2.7x, better than the original estimate of 3.4x.
Positive Outlook on Medicare Advantage
Expectations of further EBITDA expansion in 2026 as full risk cohorts mature, with no negative impact from the v28 risk model phase-in.
2025 Guidance Reaffirmed
Astrana Health reaffirmed its full-year 2025 guidance with total revenue between $3.1 billion to $3.3 billion and adjusted EBITDA between $215 million and $225 million.